(Reuters) – Relmada Therapeutics Inc said on Thursday its therapy to treat major depressive disorder did not meet the main goal of a late-stage study.
The drug, REL-1017, did not show statistically significant improvement in symptoms of depression when compared to a placebo.
Relmada will continue to study REL-1017, its lead treatment, as an adjuntive or in combination with other depression drugs.
Major depressive disorder is a chronic condition that makes patients feel low, experience guilt and worthlessness. In extreme cases, it may lead to suicide.
Shares of the company, which had a market capitalization of nearly $1 billion as of Wednesday’s close, were halted in premarket trading.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Sriraj Kalluvila)
